News | January 25, 2024
Aarti Drugs posts Q3 FY24 consolidated PAT at Rs. 36.71 Cr
Aarti Drugs has reported total income of Rs. 607.61 crores during the period ended December 31, 2023
Aarti Drugs has reported total income of Rs. 607.61 crores during the period ended December 31, 2023
The company has received Export Performance Award - API & Intermediaries Gold Star for the year 2021-22
Specialty Chemicals grew 38% YoY for FY23
Standalone Q3 FY23 revenue stood at Rs. 626.5 crore as against Rs. 594.8 crore, a growth of 5% YoY
Around 62% of the revenues came from the domestic market and 38% from the exports market for Q2 FY23 for a standalone business
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
The company received approval for 2-Methyl-5Nitro-Imidazole (2-MNI) with a committed production capacity of 4,000 MT per annum.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)